PKF supports EDX Medical Group Plc on its admission to AIM and its move from the Aquis Stock Exchange
We are pleased to have supported EDX Medical Group Plc on its successful transition from the Aquis Stock Exchange to admission to trading on AIM, with dealings in the company’s ordinary shares commencing on 13 May 2026.
Admission to AIM marks an important step in EDX’s journey in its mission to develop and deploy digitally-enabled diagnostic products and services to identify disease risk, improve clinical decision-making and accelerate the development of new medicines in the areas of cancer, heart disease and infectious diseases.
On admission, the Company had 411,844,583 ordinary shares in issue, giving an implied market capitalisation of approximately £44.3 million.
EDX Medical Group Plc is a UK‑based digital diagnostics company, focused on developing and commercialising innovative diagnostic products and services. The company’s technologies support earlier disease detection and more personalised treatment across key areas including cancer, cardiovascular and infectious diseases, underpinned by advanced biological and digital capabilities.
“We are delighted to have worked with EDX on their move from Aquis to AIM and look forward to continuing to support them in 2026 and beyond.”
Joseph Baulf, Partner, PKF Littlejohn
The PKF Littlejohn team advising on the transaction comprised Joseph Baulf, Jack Devlin and Ben Pringle
Find out more about how our Capital Markets team can support your business with IPOs, admissions and fundraises across the London Stock Exchange and international markets.
